

CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 27th May, 2022

To,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

(BY BSE LISTING CENTRE)

Sub: Disclosures pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir /Ma'am,

In accordance with Regulations 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith the Audited Financial Results of the Company for the quarter and year ended on 31st March, 2022 along with Statement of Assets and Liabilities as on 31st March, 2022 and Statement of Cash Flow for the year ended on 31st March, 2022 and Auditor's Report issued with unmodified opinion.

Further, a declaration duly signed by the Managing Director and the Chief Financial Officer of the company, pursuant to Regulation 33(3)(d) of Listing Regulations, read with SEBI Circular CIR/CFD/CMD/56/2016 dated May 27, 2016, to the effect that Auditor's Report has been issued with unmodified opinion on the Audited Financial Results of the Company for the quarter and year ended on 31st March, 2022 is also enclosed herewith.

You are requested to kindly take the same on record.

Thanking You,
Yours Faithfully

FOR SARDA PROTEINS LTD


For SARDA PROTEINS LTD.


Company Secretary

**AMIT KUMAR MODI
COMPANY SECRETARY &
COMPLIANCE OFFICER
M.NO.: 29371**

Encl: a/a

Reg. Office: B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan)
Corp. office: Inside Data Ingenious Global Limited, Station Road, Durgapura, Jaipur-302018 (Rajasthan)
Contact No.: +91-7737822222; **E Mail:** sardaproteins@yahoo.com; **Web:** www.sardaproteins.com



INDEPENDENT AUDITOR'S REPORT

Independent Auditor's Report on the Quarterly and Year to Date Standalone Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors of
SARDA PROTEINS LTD

Report on the audit of the Financial Results

Opinion

We have audited the accompanying statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2022 ("Statement") of Sarda Proteins Ltd ("the Company"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the statement;

- a. Is presented in accordance with the requirements of the Listing Regulations in this regard; and
- b. Gives a true and fair view in conformity with the applicable Indian Accounting Standards (IAS) as prescribed under section 133 of the Companies Act 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India, of the net profit and total comprehensive income and other financial information of the company for the quarter and year ended March 31, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We

believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion on the Financial Results.

Management's Responsibilities for the Financial Results

This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related Statement. The Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income and other financial information of the Company in accordance with the applicable Accounting Standards prescribed under section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulations 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement, that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, the Board of Directors are also responsible for assessing the Company's ability to continue as going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Financial Reporting process of the Company.


Auditor's Responsibilities for the audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As a part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- (a) Identify and assess the risks of material misstatement of the Statement, whether due to




fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omission, misrepresentations, or the override of internal control.

- (b) Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls system with reference to financial statements in place and the operating effectiveness of such controls.
- (c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- (d) Conclude on the appropriateness of Board of Directors'/ management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- (e) Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.
- (f) Obtain sufficient appropriate audit evidence regarding the Annual Financial Results of the company to express an opinion on the Annual Financial Results.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and others matters that may reasonably be thought to bear on our independence,



and where applicable, related safeguards.

Others Matters

The statement includes Financial Results for the quarter ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year, which were subject to limited review by us, as required under the Listing Regulations.

Our opinion on the statement is not modified in respect of the above matter.

For KHETAWAT AGARWAL & CO.

Chartered Accountants


FRN:003960C



M.L. Agarwal

Partner

Mem. No.:072854



Place : Alwar

Date: 27th May 2022

UDIN: 22072854AJTLJO4065



STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2022

S. No.	Particulars	Quarter ended			Amount in Rs. Lakhs	
		31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I.	Revenue from operation	657.64	274.00	51.59	1,075.98	1,135.99
II.	Other Income	0.97	2.93	2.67	8.54	8.39
III.	Total Revenue (I+II)	658.61	276.93	54.26	1,084.52	1,144.38
IV.	Expenses:					
	Cost of Material Consumed	-	-	-	-	-
	Purchase of Stock -in- Trade	618.29	267.01	51.54	1,028.63	1,098.06
	Changes in Inventories (Finished Goods, WIP, Stock-in-Trade)	-	-	-	-	-
	Employee Benefit Expenses	2.54	3.48	3.71	12.57	12.16
	Finance cost	-	-	0.13	0.02	0.14
	Depreciation and Amortisation Expenses	(0.01)	0.02	(0.19)	0.05	0.05
	Other expenses	7.73	0.82	2.98	7.73	27.84
	Total Expenses	628.55	271.33	58.17	1,049.00	1,138.25
V.	Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)	30.06	5.60	(3.91)	35.52	6.13
VI.	Exceptional Items	0.24	-	-	0.24	-
VII.	Profit/(Loss) before extraordinary items and tax (V-VI)	29.82	5.60	(3.91)	35.28	6.13
VIII.	Extraordinary Items	-	-	-	-	-
IX.	Profit/(Loss) Before tax (VII-VIII)	29.82	5.60	(3.91)	35.28	6.13
X.	Tax Expense:					
	(1) Current Tax	-	-	0.95	-	0.95
	(2) Deferred Tax	4.53	-	7.20	4.53	7.20
XI.	Profit/(Loss) for the period from continuing operations (VII-VIII)	25.29	5.60	(12.06)	30.75	(2.02)
XII.	Profit/(Loss) for the period from discontinuing operations	-	-	-	-	-
XIII.	Tax Expenses of discontinuing operations	-	-	-	-	-
XIV.	Profit/(Loss) from discontinuing operations (after tax) (XII-XIII)	-	-	-	-	-
XV.	Profit/(Loss) for the period (XI+XIV)	25.29	5.60	(12.06)	30.75	(2.02)
XVI.	Other Comprehensive Income	-	-	-	-	-
	A (i) Items will not be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-
	B (i) Items will be reclassified to Profit or Loss	-	-	-	-	-
	(ii) Income Tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-
XVII.	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and other comprehensive income for the period)	25.29	5.60	(12.06)	30.75	(2.02)
	Paid up Equity Share Capital (Face Value of the Share-Rs. 10 Per Share)	172.59	172.59	172.59	172.59	172.59
XVIII.	Earnings per Equity Share (For discontinued and continuing Operations)					
	(1) Basic	1.47	0.32	(0.70)	1.78	(0.12)
	(2) Diluted	1.47	0.32	(0.70)	1.78	(0.12)

Place: Jaipur
 Date : 27.05.2022

on behalf of the Board
 Sarda Proteins Ltd


Deepak Datta (DIN: 01672415)
 Managing Director



STATEMENT OF ASSETS AND LIABILITIES AS ON 31ST MARCH, 2022


Particulars		Rs. in Lakhs	
		Year ended 31.03.2022 (Audited)	Year ended 31.03.2021 (Audited)
A. ASSETS			
1. Non-Current Assets			
a) Property, Plant and Equipment		0.01	0.54
b) Capital work in progress		-	-
c) Investment Property		-	-
d) Goodwill		-	-
e) Other Intangible Assets		-	-
f) Intangible Assets under Development		-	-
g) Biological Assets other than bearer plants		-	-
h) Financial Assets			
i) Investments		0.13	0.13
ii) Trade Receivables		-	-
iii) Loans		-	-
i) Deferred Tax Assets (net)		18.09	22.62
j) Other non-current Assets		-	-
2. Current Assets			
a) Inventories		-	-
b) Financial Assets			
i) Investments		-	-
ii) Trade Receivables		20.80	77.00
iii) Cash and Cash Equivalents		32.27	13.36
iv) Bank Balances and other than (iii) above		0.31	0.03
v) Loans		173.65	99.62
v) Others		-	-
c) Current Tax Assets (net)		-	-
d) Other Current Assets		-	-
Total Assets		245.26	213.30
B. EQUITY AND LIABILITIES			
1. Equity			
a) Equity Share Capital		250.45	250.45
b) Other Equity		(11.80)	(42.55)
2. Liabilities			
Non current Liabilities			
a) Financial Liabilities			
i) Borrowings		-	-
ii) Trade Payables			
A) Total Outstanding dues to MSEs		-	-
B) Total Outstanding dues to Creditors other than MSEs		-	-
iii) Other Financial Liabilities		-	-
b) Provisions		3.00	2.09
c) Deferred Tax Liabilities (net)		-	-
d) Other Non Current Liabilities		-	-
Current Liabilities			
a) Financial Liabilities			
i) Borrowings		-	-
ii) Trade Payables			
A) Total Outstanding dues to MSEs		-	-
B) Total Outstanding dues to Creditors other than MSEs		-	-
iii) Other Financial Liabilities		-	-
b) Other Current Liabilities		3.61	3.31
c) Provisions		-	-
d) Current Tax Liabilities (net)		-	-
Total Equity and Liabilities		245.26	213.30

on behalf of the Board
Sarda Proteins Ltd



Place: Jaipur
Date: 27.05.2022

Deepak Data (DIN: 01672415)
Managing Director




CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31ST MARCH, 2022

Particulars		Rs. in Lakhs	
		Year ended 31.03.2022 (Audited)	Year ended 31.03.2021 (Audited)
CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit before Tax and Extraordinary Items		35.28	6.13
A. ADJUSTMENT FOR			
Depreciation		0.05	0.05
Interest Received		(8.54)	(8.39)
Profit on Sale of Investment		-	-
Dividend		-	-
(Profit)/Loss on sale of Fixed Assets		0.24	-
Interest Paid		0.02	0.13
Operating Profit/(Loss) before Working Capital Charges		27.05	(2.08)
ADJUSTMENT FOR			
Trade and other Receivables		(17.83)	(2.48)
Inventories		-	-
Trade & other Payables		1.21	0.19
Other Non Current Assets		-	0.22
Cash Generated from Operations		10.43	(4.15)
Direct Taxes Paid		-	0.95
Net Cash from Operating Activities		10.43	(5.10)
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital Expenditure		-	-
Sale of Fixed Assets		-	-
Profit/(Loss) on sale of Fixed Assets		0.24	-
Profit on sale of Investment		-	-
Sale of Investment		-	-
Interest Received		8.54	8.39
Dividend Received		-	-
Net Cash Received from Investing Activities		8.78	8.39
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from Long Term Borrowings		-	-
Proceeds from Short Term Borrowings		-	-
Interest Paid		(0.02)	(0.13)
Net Cash Inflow/(Outflow) from Financing Activities		(0.02)	(0.13)
Net Cash Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)		19.19	3.16
Cash & Cash Equivalents (Opening)		13.39	10.23
Cash & Cash Equivalents (Closing)		32.58	13.39

Notes:

1. The above results were approved by Audit Committee and Board of Directors in their meeting held on 27.05.2022
2. Equity Share Capital includes Rs. 77.86 Lakhs as Share Forfeiture Account.
3. Segment Results as per AS is not applicable as dealing in only one segment i.e. "Agro Products".
4. No Investor Complaints were received during the quarter ended 31-Mar-2022 nor any pending as on 01-Apr-2022.
5. The Figures for the last quarter are the balancing figures between the audited figures of the financial years ended and the published results upto the third quarter of the respective financial years.
6. Figures for the previous period have been regrouped/reclassified wherever considered necessary so as to confirm to the classification of the current period.

on behalf of the Board
Sarda Proteins Ltd



Deepak Data (DIN: 01672415)
Managing Director

Place: Jaipur
Date : 27.05.2022



CIN: L15142RJ1991PLC006353

SARDA PROTEINS LTD.

Date: 27th May, 2022

To,
BSE Limited,
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

(BY BSE LISTING CENTRE)

Sub: Declaration pursuant to Regulation 33(3) (d) of Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 ("Listing Regulations").

Ref.: Sarda Proteins Ltd, Scrip Code: 519242, Security ID: SRDAPRT.

Dear Sir / Ma'am,

DECLARATION

We, Deepak Data, Managing Director and Himanshu Gupta, Chief Financial Officer of Sarda Proteins Ltd (CIN: L15142RJ1991PLC006353) having its Registered office situated at B-536-537, Matsya Industrial Area, Alwar- 301030 (Rajasthan) hereby declare that M/s Khetawat Agarwal & Co. (FRN: 003960C), Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on Audited Financial Results for the quarter and year ended on 31st March, 2022.

This declaration is given in compliance to Regulation 33(3)(d) of the Listing Regulations as amended by the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016 read with SEBI Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

You are requested to kindly take the same on record.

**Thanking You,
Yours Faithfully**

For Sarda Proteins Ltd

For SARDAS PROTEINS LTD.


Director

Deepak Data
Managing Director
DIN: 01672415

For SARDAS PROTEINS LTD.


CFO

Himanshu Gupta
Chief Financial Officer
PAN: ANMPG4020H